DAWN Stock Recent News

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Alec Stranahan - Bank of America Soumit Roy - Jones Research Andrea Newkirk - Goldman Sachs Andres Maldonado - H.C. Wainwright Operator Ladies and gentlemen, thank you for standby.

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.

OJEMDA™  (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™  (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif.

BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025.

BALTIMORE , April 15, 2025 /PRNewswire/ -- Under Armour, Inc. (NYSE: UA, UAA) announced today that, effective April 15, Dawn N. Fitzpatrick, Eugene D.

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology-using naturally occurring canine cancers as research models-are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that's evolving faster than ever before. aAdsList.push('Art

Day One Biopharmaceuticals' Ojemda launched in Q2'24 and generated $57.2M in net product revenues in 2024. Despite reporting continued sales growth so far, DAWN's stock is near 52-week lows, perhaps in part due to a broader biotech sector pullback. A readout from the FIREFLY-2 trial of Ojemda might not be near-term, but does provide the potential for label expansion for those with a few quarters of patience.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.64 per share a year ago.

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively